Suppr超能文献

活检证实为淋巴结阳性乳腺癌患者经碳墨纹身引导下腋窝前哨淋巴结活检的可行性和准确性:一项前瞻性研究

Feasibility and accuracy of targeted axillary dissection by carbon tattooing in biopsy-proven node-positive breast cancer: A prospective study.

作者信息

Chen Minyan, Lin Zhenhu, Chen Xiaobin, Zhang Jie, Guo Wenhui, Chen Lili, Lin Yuxiang, Chen Xiaowen, Chen Cong, Fu Fangmeng, Wang Chuan

机构信息

Department of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, Fujian Province, China.

Department of General Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian, Fujian Province, China.

出版信息

Cancer. 2025 Sep 1;131(17):e70047. doi: 10.1002/cncr.70047.

Abstract

INTRODUCTION

Targeted axillary dissection (TAD) is used for less-invasive axillary staging in patients with initially node-positive breast cancer undergoing neoadjuvant chemotherapy (NACT). However, the efficacy of TAD using carbon suspension remains unclear. Here, the aim was to evaluate the feasibility and accuracy of TAD, combining sentinel lymph node biopsy (SLNB) using a single blue dye tracer with target lymph node biopsy (TLNB) using carbon suspension.

METHODS

This prospective single-institution study enrolled patients with biopsy-proven T1 to 3 N1 to 3 breast cancer between March 2020 and December 2022. Pre-NACT, black carbon suspension was injected into pathologically confirmed positive axillary lymph nodes. Post-NACT, single tracer-based SLND combined with TLNB was performed, followed by axillary lymph node dissection. Detection rates, false-negative rates, and negative predictive values were calculated for TAD, SLNB, and TLNB.

RESULTS

Of the 268 patients enrolled, 254 were included in the final evaluation, of which 86 and 93 had cN2/3 and HER2-positive disease, respectively. Detection rates were SLNB, 87.4%; TLNB, 96.9%; and TAD, 85.4%. The overall axillary pathological complete response rate was 42.1% (107 patients). False-negative rates were SLNB, 7.8%; TLNB, 12.7%; and TAD, 6.3%, with negative predictive values of 90.3%, 85.1%, and 91.9%, respectively. In seven of eight false-negative TAD cases, only one had lymph node metastasis; most showed micrometastases or isolated tumor cells. Retrieving ≥3 lymph nodes using TAD reduced the false-negative rates to 3.8%.

CONCLUSION

TAD based on carbon suspension marking and single blue dye tracer is feasible and accurate for axillary staging in initially pN+ patients with breast cancer post-NACT.

PLAIN LANGUAGE SUMMARY

Neoadjuvant chemotherapy is often used for patients with breast cancer who have positive lymph nodes. This study aimed to check if a method called targeted axillary dissection, involving the use of carbon suspension and a blue dye, is effective in identifying biopsied nodes. The researchers marked lymph nodes with carbon before treatment and performed surgeries after chemotherapy. The results showed that targeted axillary dissection is a feasible and accurate method to identify positive lymph nodes.

摘要

引言

对于接受新辅助化疗(NACT)的初始淋巴结阳性乳腺癌患者,靶向腋窝淋巴结清扫术(TAD)用于进行侵入性较小的腋窝分期。然而,使用碳悬浮液进行TAD的疗效尚不清楚。在此,目的是评估TAD的可行性和准确性,将使用单一蓝色染料示踪剂的前哨淋巴结活检(SLNB)与使用碳悬浮液的靶向淋巴结活检(TLNB)相结合。

方法

这项前瞻性单机构研究纳入了2020年3月至2022年12月期间经活检证实为T1至3 N1至3期乳腺癌的患者。在新辅助化疗前,将黑色碳悬浮液注入经病理证实的阳性腋窝淋巴结。新辅助化疗后,进行基于单一示踪剂的SLND联合TLNB,随后进行腋窝淋巴结清扫术。计算TAD、SLNB和TLNB的检出率、假阴性率和阴性预测值。

结果

在纳入的268例患者中,254例纳入最终评估,其中分别有86例和93例患有cN2/3和HER2阳性疾病。检出率分别为:SLNB为87.4%;TLNB为96.9%;TAD为85.4%。腋窝病理完全缓解率为42.1%(107例患者)。假阴性率分别为:SLNB为7.8%;TLNB为12.7%;TAD为6.3%,阴性预测值分别为90.3%、85.1%和91.9%。在8例TAD假阴性病例中的7例中,只有1例有淋巴结转移;大多数表现为微转移或孤立肿瘤细胞。使用TAD获取≥3个淋巴结可将假阴性率降至3.8%。

结论

基于碳悬浮液标记和单一蓝色染料示踪剂的TAD对于初始pN+乳腺癌患者新辅助化疗后的腋窝分期是可行且准确的。

通俗易懂的总结

新辅助化疗常用于淋巴结阳性的乳腺癌患者。本研究旨在检查一种名为靶向腋窝淋巴结清扫术的方法,该方法涉及使用碳悬浮液和蓝色染料,在识别活检淋巴结方面是否有效。研究人员在治疗前用碳标记淋巴结,并在化疗后进行手术。结果表明,靶向腋窝淋巴结清扫术是识别阳性淋巴结的一种可行且准确的方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验